Ken Griffin Lava Therapeutics Nv Put Options Transaction History

Citadel Advisors LLC

  • $550 Billion
  • Q2 2025

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$1.57 - $2.29 $56,991 - $83,127
-36,300 Reduced 99.18%
300 $0
Q2 2024

Aug 14, 2024
SELL
$1.8 - $3.37 $11,880 - $22,242
-6,600 Reduced 15.28%
36,600 $65,000
Q1 2024

May 15, 2024
BUY
$1.53 - $4.03 $66,096 - $174,096
43,200 New
43,200 $143,000

Others Institutions Holding LVTX

# of Institutions
21
Shares Held
4.84M
Call Options Held
17.9K
Put Options Held
200
View Full List

About LAVA Therapeutics NV

LVTX Quotes by TradingView
  • Ticker LVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,797,700
  • Market Cap $38.7M
  • Description
  • LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...
More about LVTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email